Mexico Childhood Obesity Treatment Market Industry Trends and Forecast to 2034: Segmented by (Treatment, Age, End User, Region) - Growth, Market Size, Future Prospects & Competitive Analysis, 2024-2034
Overview
Market Dashboard
Mexico · 2024–2034 · placeholder estimates
Values shown here are placeholder estimates, not researched figures. Researched 2024 historical, 2025 base-year and 2026–2034 forecast values are prepared with the
full report.
Estimate 2024$20.7 MnPlaceholder estimate
Estimate 2025$24.1 Mn1.4% of the global market
Projected 2034$93.7 Mn 289.2%Adds $69.6 Mn over 9 forecast years
CAGR 2025–203416.3%Faster than 80% of 186 Pharmaceuticals markets here
Key players5
Mexico is 1.38% of the global market.
In Latin America, the largest is Brazil at $50.9 Mn.
4 in MexicoSource: ClinicalTrials.gov, Studies recruiting, active or not yet recruiting, in Mexico. Retrieved 12 Nov 2026.
Formats
PDF, PPTX, XLSX
Sizes and growth here are placeholder estimates, not researched figures. Researched figures come with the full report.
The Mexico Childhood Obesity Treatment Market Analysis Executive Summary
Childhood obesity treatment includes family programs, nutrition support, medicines and, for some teens, surgery to help children reach a healthier weight.
Key segments of the childhood Obesity Treatment market include treatment (Lifestyle and Behavioral Programs, Medication and Bariatric Surgery) and age (Children 6-11 and Adolescents 12-17).
Mexico Childhood Obesity Treatment market size, 2024–2034. Placeholder estimates; researched figures come with the full report. Source: Acuitas Health Analytics.
Rising rates of obesity and type 2 diabetes, strong clinical results for new weight-loss medicines and growing acceptance of obesity as a chronic disease are driving the childhood Obesity Treatment market. Wider insurance coverage and more doctors trained in obesity care are adding to demand.
Opportunity
Oral formulations, combination therapies and use in heart, kidney and liver disease open new growth paths for the childhood Obesity Treatment market, especially in fast-growing emerging economies.
Market Restraints
High treatment prices, limited reimbursement, supply shortages and side effects that lead some patients to stop treatment hold back the childhood Obesity Treatment market. Long-term safety data and lifestyle support are still needed for many patients.
Competitive Landscape for Childhood Obesity Treatment Market in Mexico
The childhood Obesity Treatment market is moderately concentrated. Leading companies compete on product innovation, clinical evidence, pricing and geographic reach, and use partnerships and acquisitions to expand their portfolios.
Healthcare Policies and Regulatory Landscape for Childhood Obesity Treatment Market in Mexico
Childhood Obesity Treatment in Mexico: rules, payment and research
Medicines need a sanitary registration from COFEPRIS before sale.[1] Public care comes through IMSS for formal workers, ISSSTE for public employees, and IMSS-Bienestar for people without social security.[2] ClinicalTrials.gov lists 4 studies on Childhood Obesity Treatment that are recruiting, active or about to start in Mexico.[3] Obesity (adults): 37.4% of adults in 2024, the latest WHO figure for Mexico.[4]
Regulators such as the US FDA, the European Medicines Agency and national drug authorities set approval, pricing and safety rules for childhood Obesity Treatment. Reimbursement decisions by public payers and insurers shape how fast new therapies reach patients in Mexico.
2.2 Market Size, Growth Prospects and Key findings
3 Market Dynamics
3.1 Market Growth Drivers Analysis
3.2 Market Restraints Analysis
4 Market Segmentation
4.1 By Treatment
4.2 By Age
4.3 By End User
5 By Market Share
5.1 Market Analysis, Insights and Forecast – By Revenue
6 Competitive Landscape
6.1 Major Top Market Players Products in Pipeline
6.2 R&D Initiatives
6.3 Notable recent Deals
6.3.1 Strategic Divestments
6.3.2 Mergers & Acquisitions
6.3.3 Partnerships
6.3.4 Joint Ventures
7 Key Company Profiles
7.1 Novo Nordisk
7.2 Eli Lilly and Company
7.3 Rhythm Pharmaceuticals
7.4 Kurbo (WW International)
7.5 Teladoc Health
8 Healthcare Policies and Regulatory Landscape
8.1 Policy changes and Reimbursement scenario
8.2 Government Initiatives / Intervention programs
The childhood Obesity Treatment market can be segmented based on various criteria, including treatment, age and end user. Here's a breakdown of the market segmentation
Obesity (adults): 37.4% of adults (2024). World: 16.2% of adults (2024). 2nd highest of the 7 countries we cover in Latin America.[1]
Health spending per person: 761 US$ per person (2023). World: 1,317 US$ per person (2023). 4th highest of the 7 countries we cover in Latin America.[2]
Doctors: 2.59 per 1,000 people (2022). World: 1.86 per 1,000 people (2022). 3rd highest of the 7 countries we cover in Latin America.[3]
How big is the Childhood Obesity Treatment market in Mexico?
Placeholder estimate: about $24.1 Mn in 2025, rising to about $93.7 Mn by 2034. These are early estimates, not researched figures; the researched values come with the full report.
How fast is the Childhood Obesity Treatment market in Mexico growing?
Placeholder estimate: about 16.3% a year (CAGR, 2025–2034). The researched growth rate comes with the full report.
What segments does the Childhood Obesity Treatment market report cover?
The report splits the market by treatment (Lifestyle and Behavioral Programs, Medication, Bariatric Surgery), age (Children 6-11, Adolescents 12-17) and end user (Hospitals, Specialty Clinics, Retail Pharmacies, Online Pharmacies).
Who are the key players in the Childhood Obesity Treatment market?
Key players include Novo Nordisk A/S, Eli Lilly and Company, Rhythm Pharmaceuticals, Kurbo (WW International) and Teladoc Health.
What is driving the Childhood Obesity Treatment market?
Rising rates of obesity and type 2 diabetes, strong clinical results for new weight-loss medicines and growing acceptance of obesity as a chronic disease are driving the childhood Obesity Treatment market.
Who regulates Childhood Obesity Treatment in Mexico?
Medicines need a sanitary registration from COFEPRIS before sale. Source: COFEPRIS. Checked 14 Nov 2026.
How is healthcare paid for in Mexico?
Public care comes through IMSS for formal workers, ISSSTE for public employees, and IMSS-Bienestar for people without social security. Source: Mexican Social Security Institute (IMSS). Checked 14 Nov 2026.
How many clinical trials on Childhood Obesity Treatment are running in Mexico?
4 studies are recruiting, active or about to start in Mexico, according to ClinicalTrials.gov. Source: ClinicalTrials.gov, Studies recruiting, active or not yet recruiting, in Mexico. Retrieved 12 Nov 2026.
What does WHO report for Mexico?
Obesity (adults): 37.4% of adults in 2024, the latest WHO figure. Source: WHO Global Health Observatory, Obesity (adults) (% of adults). Retrieved 22 Nov 2026.
How many people in Mexico are 65 or older?
8.5% of people were 65 or older in 2025. Source: World Bank Open Data, Population ages 65 and above (% of total population), from UN population estimates. Retrieved 22 Nov 2026.